Relay Therapeutics Income Statement (2019-2026) | RLAY

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.84M0.67M0.57M0.42M0.36M0.34M0.25M0.23M0.12M25.20M-0.00M10.01M7.68M0.68M7.00M3.00M
Operating items
Research & Development (Quarter)
45.15M44.97M51.91M51.67M60.51M66.90M67.28M82.83M88.20M81.49M77.50M82.40M91.99M76.62M68.08M73.81M63.90M68.26M55.41M70.56M
Selling, General & Administrative (Quarter)
14.42M14.68M15.55M16.07M17.46M16.07M16.37M19.58M20.12M18.48M16.77M19.80M20.14M19.75M16.90M18.74M13.63M12.13M12.21M11.03M
Other Operating Expenses (Quarter)
134.85M2.00M0.84M-4.59M0.20M3.26M-10.54M-1.00M-2.15M-1.20M-2.07M-1.83M-11.37M
Operating Expenses (Quarter)
194.42M61.66M68.29M63.14M78.18M86.24M73.10M101.40M106.17M98.78M92.19M100.37M100.76M96.37M84.98M92.55M77.52M80.39M67.63M81.59M
Operating Income (Quarter)
-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M
EBIT (Quarter)
-193.58M-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M
Non-operating items
Interest & Investment Income (Quarter)
0.18M0.16M0.27M0.70M1.00M1.71M5.37M6.94M7.56M7.84M8.70M8.95M8.55M8.27M8.97M7.81M7.11M6.41M5.71M5.35M
Other Non Operating Income (Quarter)
0.18M0.16M0.27M0.68M1.02M1.72M5.35M6.94M7.54M7.84M8.70M8.98M8.54M8.26M8.97M7.80M6.47M6.24M5.74M5.30M
Non Operating Income (Quarter)
0.00M0.16M0.83M0.68M1.02M0.01M5.35M6.94M-0.01M-0.00M8.70M8.98M8.54M8.26M8.97M0.01M-0.63M6.24M0.03M5.30M
Net income details
EBT (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M-73.24M
Profit After Tax (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.79M-84.17M-67.50M-94.24M-98.50M-65.73M-83.50M-81.39M-92.21M-88.11M-76.00M-77.06M-70.38M-74.15M-54.89M-73.29M
Income from Continuing Operations (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M-73.24M
Consolidated Net Income (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M-73.24M
Income towards Parent Company (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M-73.24M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-193.40M-60.83M-67.46M-62.05M-76.81M-84.18M-67.48M-94.24M-98.49M-65.73M-83.50M-81.41M-92.21M-88.09M-76.00M-77.06M-69.74M-73.98M-54.92M-73.24M
Additional items
EPS (Basic) (Quarter)
-2.10-0.66-0.62-0.57-0.71-0.76-0.55-0.78-0.81-0.54-0.67-0.62-0.69-0.63-0.42-0.46-0.41-0.43-0.31-0.41
EPS (Weighted Average and Diluted) (Quarter)
-0.66-0.62-0.57-0.71-0.76-0.55-0.78-0.81-0.54-0.67-0.62-0.69-0.63-0.42-0.46-0.41-0.43-0.31-0.41
Shares Outstanding (Weighted Average) (Quarter)
91.19M92.69M95.14M108.29M108.64M110.91M112.23M121.32M121.68M122.23M122.58M130.84M131.83M134.65M142.87M169.23M171.26M172.39M171.59M179.85M
Shares Outstanding (Diluted Average) (Quarter)
92.69M109.29M
EBITDA (Quarter)
-193.47M-60.76M-68.55M-70.18M-79.48M-85.66M-64.53M-89.62M-98.78M-63.04M-80.31M-82.35M-92.39M-84.26M-79.50M-76.04M-70.58M-73.49M-54.65M-73.46M
Interest Expenses (Quarter)
0.02M0.00M
Shares Outstanding (Quarter)
92.55M92.80M108.21M108.43M108.81M120.81M121.11M121.48M121.94M123.16M127.46M132.30M133.32M166.89M167.76M170.48M171.69M172.63M173.87M189.21M